STOCK TITAN

Natera, Inc. - NTRA STOCK NEWS

Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.

Natera, Inc. (Symbol: NTRA) is a leading diagnostic and research company based in San Carlos, CA, driven by a commitment to advance the science and application of prenatal testing. In the information age, medical diagnostics have lagged behind in adopting new technologies, but Natera is changing that narrative. The company specializes in preconception and prenatal genetic testing services, providing couples with crucial information throughout the pregnancy journey.

Natera offers a comprehensive range of tests, including Preimplantation Genetic Diagnosis (PGD) for IVF and Non-Invasive Prenatal Testing (NIPT). Their Panorama NIPT is particularly notable for its ability to screen for chromosomal abnormalities in a fetus, even in twin pregnancies, typically through a simple blood draw from the mother. Another significant product is the Horizon Carrier Screening (HCS), which determines carrier status for numerous severe genetic diseases that could be passed on to offspring.

The company's innovative approach leverages advances from the Human Genome Project and is powered by proprietary bioinformatics algorithms. This technology enables highly accurate genetic testing results. Natera's portfolio also includes the Signatera Molecular Residual Disease (MRD) Test, designed to detect circulating tumor DNA in cancer patients, helping to assess molecular residual disease and monitor recurrence. Additionally, the Prospera test assesses organ transplant rejection.

Through its pioneering genetic testing services and experienced genetic counseling, Natera provides valuable insights that help in informed decision-making for pregnancies and medical conditions. The company continues to make significant strides in the field of medical diagnostics, driven by a passion for innovation and excellence.

Rhea-AI Summary

Natera announced new data from the CIRCULATE-Japan trial, revealing a 75% detection rate of colorectal cancer recurrence from a single blood draw four weeks post-surgery. This update, presented at the SSO 2022 conference, indicates improved outcomes for patients identified through Natera's Signatera test. The CIRCULATE-Japan study is the largest clinical trial focusing on molecular residual disease in colorectal cancer, enrolling over 3,300 patients to date. Additionally, Natera activated the CIRCULATE-US trial to further explore MRD-guided treatment strategies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
-
Rhea-AI Summary

Natera, Inc. (NASDAQ: NTRA) announced a $5 million investment in its stock by Roelof Botha, lead independent director and partner at Sequoia Capital, reflecting his confidence in the company’s future. Botha has worked closely with Natera for 15 years, emphasizing his commitment to its strategic and commercial execution. Additionally, Natera's executives and non-employee directors will convert their cash compensation to equity for the remainder of 2022. This move indicates a strong internal belief in the company's potential, focusing on genetic testing's role in healthcare.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.5%
Tags
none
-
Rhea-AI Summary

A jury in Delaware District Court ruled that both CareDx and Natera engaged in false advertising. CareDx misled investors and physicians regarding its funding of a scientific publication, which it falsely claimed was independent. Additionally, there were no findings regarding the scientific validity of Natera's data. In parallel litigation, a federal court invalidated all patents that CareDx asserted against Natera, who is pursuing its own patent enforcement. Final monetary relief from the jury's decision is still pending.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.52%
Tags
none
Rhea-AI Summary

Natera, Inc. (NASDAQ: NTRA) announced a significant change in compensation for its executive leaders and board of directors, who will receive stock instead of cash salaries for the remainder of 2022. This decision reflects their confidence in the company's strong fundamentals and business outlook. Key figures include CEO Steve Chapman, CFO Mike Brophy, and COO Bob Schueren, among others. Natera focuses on cell-free DNA testing across oncology, women's health, and organ health, emphasizing a commitment to personalized diagnostics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.93%
Tags
none
-
Rhea-AI Summary

Natera, Inc. (NASDAQ: NTRA) has achieved a significant milestone in its BESPOKE CRC study, enrolling over 1,000 patients across more than 100 sites in the U.S. The study focuses on the impact of Signatera, a custom ctDNA test, in managing colorectal cancer (CRC). Target enrollment is over 2,000 patients, with a follow-up period of up to 5 years. Investigators plan an interim analysis in late 2022. This study aims to provide real-world insights into personalized treatment decisions for CRC patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.52%
Tags
none
-
Rhea-AI Summary

Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, has announced an investor call on March 10, 2022, to address a recent misleading report by short sellers. CFO Mike Brophy will provide updates and clarify the misinformation. The call will be held at 4:00 a.m. PT (7:00 a.m. ET), with a live dial-in option available for participants. A replay of the webcast will be accessible post-event on Natera's investor relations site. Natera emphasizes its commitment to providing accurate genetic testing validated by extensive peer-reviewed research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.79%
Tags
conferences
Rhea-AI Summary

Natera, based in Austin, Texas, responded strongly to a report by Hindenburg Research, labeling it misleading and an attempt by short sellers to profit from negative sentiments. The company emphasizes its commitment to compliance and the efficacy of its testing procedures, supported by over 100 peer-reviewed studies involving more than 1.3 million patients. Natera highlights its high performance in recent studies and maintains an A+ BBB rating, demonstrating a focus on patient satisfaction and operational integrity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-32.79%
Tags
none
-
Rhea-AI Summary

Natera, Inc. (NTRA) reported Q4 2021 revenues of $173.0 million, a 53.9% increase year-over-year, with full-year revenues reaching $625.5 million, up 60%. Product revenues rose 51.1% in Q4, driven by a 48.7% increase in tests processed. However, total operating expenses surged 72.8% in Q4, leading to a net loss of $140.6 million or ($1.48) per share. The company holds $914.5 million in cash, forecasting 2022 revenues between $770 million and $790 million with an approximate gross margin of 46% to 48%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.62%
Tags
-
Rhea-AI Summary

Natera, Inc. (NASDAQ: NTRA) announced it will release its fourth quarter and year-end 2021 financial results on February 24, 2022, after market close. A conference call will follow at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results and financial outlook. Natera is a leader in cell-free DNA testing, focused on oncology, women's health, and organ health. Their tests are backed by over 100 peer-reviewed publications, ensuring high accuracy, with operations in Texas and California.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
Rhea-AI Summary

Natera, Inc. (NASDAQ: NTRA) announced the results of a large real-world study confirming the effectiveness of its Prospera donor-derived cell-free DNA (dd-cfDNA) test for kidney transplant patients. Conducted across 33 clinics with 879 patients, the study reported a 64% positive predictive value in detecting active rejection among those with high-risk results. The findings, published in Transplantation Proceedings, indicate that dd-cfDNA testing can enhance physician decision-making in managing transplant patients. This adds to existing evidence supporting the Prospera test's clinical utility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.11%
Tags
none

FAQ

What is the current stock price of Natera (NTRA)?

The current stock price of Natera (NTRA) is $161.88 as of December 20, 2024.

What is the market cap of Natera (NTRA)?

The market cap of Natera (NTRA) is approximately 21.2B.

What does Natera, Inc. specialize in?

Natera specializes in preconception and prenatal genetic testing services, including Non-Invasive Prenatal Testing (NIPT) and Horizon Carrier Screening (HCS).

Where is Natera, Inc. headquartered?

Natera, Inc. is headquartered in San Carlos, California.

What is the Panorama Non-Invasive Prenatal Test (NIPT)?

The Panorama NIPT screens for chromosomal abnormalities in a fetus, including twin pregnancies, typically through a blood draw from the mother.

What is the Horizon Carrier Screening (HCS)?

Horizon Carrier Screening (HCS) determines if an individual is a carrier for severe genetic diseases that could be passed to their children.

What is the Signatera Molecular Residual Disease (MRD) Test?

The Signatera MRD Test detects circulating tumor DNA in previously diagnosed cancer patients to assess molecular residual disease and monitor recurrence.

What is the purpose of the Prospera test?

The Prospera test is designed to assess organ transplant rejection.

How has Natera advanced genetic testing?

Natera has leveraged advances from the Human Genome Project and sophisticated proprietary bioinformatic algorithms to deliver highly accurate genetic testing results.

Does Natera offer genetic counseling services?

Yes, Natera provides experienced genetic counseling services to help patients understand their test results and make informed decisions.

What industries does Natera serve?

Natera primarily serves the medical diagnostics and research industries, focusing on prenatal, cancer, and transplant testing.

What makes Natera's tests unique?

Natera's tests are unique due to their high accuracy, leveraging proprietary bioinformatics technology and advances from the Human Genome Project.

Natera, Inc.

Nasdaq:NTRA

NTRA Rankings

NTRA Stock Data

21.17B
126.55M
3.52%
93.94%
2.83%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
AUSTIN